• DAY:
• Place：Montreal, QC, Canada
• CALPAIN, NOT CASPASE, IS THE CAUSATIVE PROTEASE FOR HYPOXIC DAMAGE IN CULTURED MONKEY RETINAL CELLS
• E. Nakajima 1,2, K. B. Hammond 1,2, T.R. Shearer 2, M.Azuma 1,2.
  1 Senju Pharmaceutical Co., Ltd.
  2 Oregon Health & Science University

Presentation date: July 20, 2010

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Sunday, May 2, 2010 8:30 - 10:15 AM
  371/D858 –
  Effect of Recombinant Galectin-3 on Corneal Wound Healing
  F. Yano, C. Yabuta, M. Azuma. Senju Pharmaceutical, Kobe, Japan.
  
  Sunday, May 2, 2010 11:15 AM - 1:00 PM
  539/A220 –
  Patient Selection Criteria for Drug Efficacy Studies on Dry AMD
  A. Fujii1, K. Chung2A, M. Azuma1,2B, T.R. Shearer2B.
  1 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Beaverton, OR; A Department of Ophthalmology, B Department of Integrative Biosciences, 2 Oregon Health & Science University, Portland, OR.
  
  Sunday, May 2, 2010 11:15 AM - 1:00 PM
  821/D1033 –
  Calpain Inhibition Confers Histological and Functional Neuroprotection to Retinal Ganglion Cells in Experimental Optic Neuritis
  A.W. Smith1, J.T. Butler1, B. Rohrer2, M. Azuma3, J. Inoue4, N.L. Banik5.
  1 Neuroscience, Medical University of South Carolina, Charleston, SC; 2 Ophthalmology, Med Univ of South Carolina, Charleston, SC; 3 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co Ltd, Kobe, Japan; 4 Senju USA Inc, Woodland Hills, CA; 5 Neurology, Medical Univ of South Carolina, Charleston, SC.
  
  Tuesday, May 4, 2010 8:30 - 10:15 AM
  2610/A417 –
  Involvement of Calpain in Ionomycin-Induced Cell Death in Cultured Mouse Lens Epithelial Cells
  T. Nakajima1, T.R. Shearer2, M. Azuma2,3.
  1 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2 Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR; 3 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Beaverton, OR.
  
  Tuesday, May 4, 2010 1:45 - 3:30 PM
  3406/D992 –
  FK962 Enhances Axonal Regeneration in Cultured Rat Trigeminal Ganglion Cells
  Y. Kishimoto, C. Yabuta, M. Azuma.
  Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Kobe, Japan.
  
  Tuesday, May 4, 2010 1:45 - 3:30 PM
  3407/D993 –
  Topical Application of FK962 Enhances Axonal Elongation and Corneal Sensitivity in a Rabbit Model of LASIK Surgery
  T. Oka, F. Yano, Y. Tamada, C. Yabuta, M. Azuma. Senju Pharmaceutical Co., Ltd., Kobe, Japan.
  
  Wednesday, May 5, 2010 8:30 - 10:15 AM
  4178/D729 –
  Functions of Primate Lacritin: Enhanced Secretion of Tear Proteins From Lacrimal Acinar Cells and Promotion of Corneal Epithelial Cell Adhesion
  A. Morimoto-Tochigi1, T. Nakajima1, A. Fujii2, T.R. Shearer3, M. Azuma2,3.
  1 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2 Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Beaverton, OR; 3 Department of Integrative Biosciences, Oregon Health & Sciences University, Portland, OR.
  
  Thursday, May 6, 2010 8:30 - 10:15 AM
  5303/A231 –
  A Hydrogel Ring as a New Transscleral Drug Delivery System to the Posterior Eye
  Y. Shikamura1,2, A. Ohtori1, T. Matsunaga3, Y. Yamazaki3, T. Sato3, K. Tojo2.
  1 Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2 Bioscience and Bioinformatics, Kyushu Institute of Technology, Fukuoka, Japan; 3 Research Laboratories, Seed Co., Ltd., Saitama, Japan.

• DAY:
• Place：Anaheim, CA, U.S.A.
• PACAP induces axonal elongation in cultured monkey trigeminal ganglion cells
  (Presentation:2010.04.26)
• ○E. Nakajima1,2, Ryan D. Walkup1,2, Thomas　R. Shearer2, M. Azuma1,2.
  1 Senju Pharmaceutical Co,.Ltd., 2 Oregon Health & Science University

• DAY:
• Place：Suita Campus, Osaka University
• Contribution of experimental animal technologist to Refinement and Reduction
• Yuji Sakamoto
  Senju Pharmaceutical Co,.Ltd., The Japanese Association for Experimental Animal Technologists

• DAY:
• Place：Hong Kong Convention and Exhibition Centre, Hong Kong, China
• ①Effect of Topical Bromfenac Sodium 0.1% Ophthalmic Solution on Laser-Induced Choroidal Neovascularization in Mice
  ②Effect of Bromfenac Sodium on Acute and Chronic Uveitis in Rabbits
• ①T. Kida1, T. Ogawa2, H. Sakaki1, J. Han3, C. K. Song3, T. R. McNamara3.
  1 Senju Pharmaceutical Co Ltd, 2 Senju USA, Inc. 3 ISTA Pharmaceuticals, Inc., Irvine, CA.
  ②T. Ogawa1, T. Kida2.
  1 Senju USA, Inc, 2 Senju Pharmaceutical Co., Ltd.

• DAY:
• Place：Alumni Hall, 4227 Fifth Avenue, Pittsburgh, Pennsylvania, 15260
• Design of calpain inhibitors to enhance the penetration to the retina
• Y.Shirasaki, H.Takahashi, M.Yamaguchi, J.Inoue.
  Senju Pharmaceutical Co., Ltd.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Corneal Endothelial Cell Proliferation is Enhanced by a Single Injection of Connexin 43 siRNA in a Primate Endothelial Injury Model

N.Koizumi1,2, Y.Nakano2,3, Y.Sakamoto4, N.Okumura2, P.Dai3, H.Tsuchiya5, R.Torii5, S.Kinoshita2, T.Takamatsu3.
1 Research Center for Regenerative Medicine, Doshisha University; Kyoto, Japan, 2Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 3Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 4Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan, 5Research Center for Animal Life Science, Shiga University of Medical Science; Otsu, Japan.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Effects of Bromfenac Sodium on Acute and Chronic Uveitis in Rabbits
• T. Ogawa1, T. Kida2, J. Han3, C.K. Song3, T.R. McNamara3.
  1 Senju USA, Inc., Woodland Hills, CA; 2Research laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 3ISTA Pharmaceuticals, Inc., Irvine, CA.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Secretion of Lacritin from Cultured Monkey Lacrimal Acinar Cells
• A. Tochigi1, R.D. Walkup1, T. Nakajima1, T.R. Shearer2, M. Azuma1,2.
  1 Senju Pharmaceutical Co., Ltd., 3 Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Involvement of NFkB and STAT6 on Eotaxin-1, IL-8 and RANTES production in human conjunctival fibroblasts and epithelial cells
• O.Sakai, H.Takahashi, Y.Tamada, J.Inoue, M.Azuma.
  Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Induction of Tube Formation by Angiogenic Factors Secreted From Cultured RPE Cells During Hypoxia
• T. Nakajima1, E. Nakajima1, T.R. Shearer2, M. Azuma1,2.
  1 Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2 Department of Integrative Biosciences, Oregon Health & Science University, Portland, OR.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A.
• Concentration Distribution in the Posterior Ocular Tissue after Drug Instillation
• Y.Shikamura1,, A.Ohtori1, K.Tojo2.
  1 Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2 Biosciemical Science and Bioinformatics, Kyushu Institute of Technology, Fukuoka, Japan.

• DAY:
• Place：San Diego, CA, U.S.A.
• Calpain involvement in monkey retinal cell damage due to hypoxia
• Emi Nakajima1,2, Thomas R. Shearer2, Mitsuyoshi Azuma1,2. 1Senju Pharmaceutical Co., Ltd.; 2Oregon Health & Science University

• DAY:
• Place：Denver, Colorado, U.S.A.
• Evaluations of the Human COX-1 and COX-2 Inhibition for Amfenac, Bromfenac, Diclofenac and Ketorolac.
• Tetsuo Kida1, Takahiro Ogawa2, Timothy R. McNamara3, Clara K. Song3, James A.Gow3.
  1Research Laboratories, Senju Pharmaceutical Co Ltd, Kobe, Japan; 2Senju USA, Inc., Woodland Hills, CA; 3Medical Affairs, ISTA Pharmaceuticals, Inc., Irvine, CA.

• DAY:
• Place：Fort Lauderdale, Florida, U.S.A. : May 6-10, 2007
• ①Preclinical Pharmacokinetics of Difluprednate Emulsion
  ②Efficacy of Difluprednate Ophthalmic Emulsion in Preclinical Studies of Uveitis
  ③Preclinical Toxicity of Difluprednate Emulsion
  ④Ocular Distribution and Metabolism After Instillation of Difluprednate Ophthalmic Emulsion in Rabbits
  ⑤Difluprednate Emulsion Inhibits Postoperative Inflammation in Rabbit Paracentesis Model
  ⑥Ecabet Sodium Promotes MUC5AC Secretion in Rabbit Tears
  ⑦Species Difference in Corneal Metabolism of Fluorometholone
  ⑧Polylactic Acid for Visualizing Vitreous Body During Vitrectomy
  ⑨Involvement of Cycloxygenase-1 and -2 in Ocular Inflammation and Pain Using a Rabbit Model
  ⑩Long-term Observation of Cultivated Corneal Endothelial Transplantation in Primates
  ⑪Expression of Cell Cycle Molecules in Primate Corneal Endothelial Cells and Primate Cultivated Corneal Endothelial Cells
  ⑫Detection of Mutations in Quinolone Resistance-Determining Regions in Methicillin-Susceptible and -Resistant Clinical Isolates of Staphylococcus epidermidis : Effects of the Mutations on Fluoroquinolone MICs
• ①J.Inoue, M.Yamaguchi, H.Sakaki, T.Kida, T.Tajika, K.Inada, A.Ohtori.
  Research Laboratories, Senju Pharmaceutical Co Ltd, Kobe, Japan.
  ②A.Okumura1, M.Tsuzuki2, T.Wada2, T.Kida2, T.Tajika2, H.Sakaki2, A.Ohtori2.
  1Strategic R&D Planning, Senju Pharmaceutical Co Ltd, Osaka, Japan; 2Research Laboratory, Senju Pharmaceutical Co Ltd, Kobe, Japan.
  ③H.Sakaki, S.Nemoto, T.Kida, T.Tajika, A.Ohtori.
  Research Laboratories, Senju Pharmaceutical Co.,Ltd., Kobe, Japan.
  ④T.Tajika, M.Kimura, T.Kida, H.Sakaki, A.Ohtori.
  Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan.
  ⑤T.Kida, H.Takahashi, M.Tsuzuki, T.Tajika, H.Sakaki, A.Ohtori.
  Research Laboratories, Senju Pharmaceutical Co., Ltd., Kobe, Japan.
  ⑥C.Mito1, H.Tokushige1, T.Kida1, H.Sakaki1, T.Ogawa2.
  1Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2Senju USA Inc., Encino, CA.
  ⑦Y.Shirasaki1A, T.Tajika1A, H.Takahashi1B, T.Kida1A, H.Sakaki1A.
  A Laboratory for Preclinical Research; B Drug Discovery Research Laboratory; 1 Senju Pharmaceutical Co., Ltd., Kobe, Japan.
  ⑧T.Sakamoto1, T.Yamashita1, K.Yamakiri1, M.Miura2, H.Enaida2, T.Ishibashi2, I.Atsumi3, K.Matsuhisa3, Y.Sakamoto3, T.Kida3.
  1Ophthalmology, Kagoshima University School of Medicine, Kagoshima, Japan; 2Ophthalmology, Kyushu University, Fukuoka, Japan; 3Senju Pharmaceutical Co. Ltd., Kobe, Japan.
  ⑨T.Ogawa1, T.Kida1, C.K. Song2, J.A. Gow2, T.R. McNamara2.
  1Research and Development, Senju USA, Inc., Encino, CA; 2Medical Affairs, ISTA Pharmaceuticals, Inc., Irvine, CA.
  ⑩N. Koizumi1,4, Y. Sakamoto2, N. Okahara3, H. Tsuchiya3, H. R. Torii3, Cooper LJ4, S. Kinoshita4.
  1Research Center for Regenerative Medicine, Doshisha University; 2Drug Discovery Research Laboratory, Senju Pharmaceutical Co., Ltd.; 3Research Center for Animal Life Science, Shiga University of Medical Science; 4Ophthalmology, Kyoto Prefectural University of Medicine.
  ⑪Naoki Okumura1, Noriko Koizumi1,2, Akira Matsuda1, Yuji Sakamoto3, Shigeru Kinoshita1.
  1Ophthalmology, Kyoto Prefectural University of Medicine; 2Research Center for Regenerative Medicine, Doshisha University; 3Drug Discovery Research Laboratory, Senju Pharmaceutical Co., Ltd.
  ⑫Y. Minagawa1, S. Hatou2, M. Yamada2.
  1Senju Pharmaceutical Co. Ltd.; 2National Institute of Sensory Organs, National Tokyo Medical Center.